Select country change
Shopping cart (0 , 0,00 ) Menu Search
Manufactured by BioVendor

hsa-miR-210-3p miREIA

  • Regulatory status:RUO
  • Type:miREIA – miRNA enzyme immunoassay
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price


New RDM0029H 96 wells (1 kit)
PubMed Product Details
Technical Data

Type

miREIA – miRNA enzyme immunoassay

Applications

Serum, Plasma-EDTA, Whole blood, Cell culture lysates, PBMC

Sample Requirements

10 µl/well

Shipping

At ambient temperature. Upon receipt, store the product at the temperature recommended below.

Storage/Expiration

Store the complete kit at 2 – 8 °C. Under these conditions, all components are stable until the expiration date (see label on the box).

Calibration Range

25 – 0.78 amol/μl

Limit of Detection

0.13 amol/μl

Summary

Features

  • It is intended for research use only
  • The total assay time is less than 2.5 hours
  • The kit measures hsa-miR-210-3p isolated from human blood
  • Assay format is 96 wells
  • Standard is synthetic miRNA-based
  • Components of the kit are provided ready to use, concentrated or dried

Research topic

Oncology, Reproduction

References to Summary

References to miR-210-3p

  • Yan, Yan, et al. "Elevation of circulating miR-210-3p in high-altitude hypoxic environment." Frontiers in Physiology 7 (2016): 84.
  • Bavelloni, Alberto, et al. "MiRNA-210: A current overview." Anticancer research 37.12 (2017): 6511-6521.
  • Zhang, Jian, et al. "Exosome and exosomal microRNA: trafficking, sorting, and function." Genomics, proteomics & bioinformatics 13.1 (2015): 17-24.
  • Cai, Haiqing, et al. "Prognostic evaluation of microRNA-210 expression in pediatric osteosarcoma." Medical oncology 30.2 (2013): 499.
  • Qin, Qin, Wei Furong, and Li Baosheng. "Multiple functions of hypoxia-regulated miR-210 in cancer." Journal of Experimental & Clinical Cancer Research 33.1 (2014): 50.
  • Wang, Jian, et al. "Elevated expression of miR-210 predicts poor survival of cancer patients: a systematic review and meta-analysis." PloS one 9.2 (2014)
  • Zhao, An, et al. "Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma." Experimental and molecular pathology 94.1 (2013): 115-120.
  • Yoshino, Hirofumi, et al. "microRNA-210-3p depletion by CRISPR/Cas9 promoted tumorigenesis through revival of TWIST1 in renal cell carcinoma." Oncotarget 8.13 (2017): 20881.
  • Li, Guorong, et al. "Detection of urinary cell-free miR-210 as a potential tool of liquid biopsy for clear cell renal cell carcinoma." Urologic Oncology: Seminars and Original Investigations. Vol. 35. No. 5. Elsevier, 2017.
  • Dong, Fan, et al. "Dysregulation of miRNAs in bladder cancer: Altered expression with aberrant biogenesis procedure." Oncotarget 8.16 (2017): 27547.
  • Zeng, Lili, et al. "MicroRNA-210 as a novel blood biomarker in acute cerebral ischemia." Front Biosci (Elite Ed) 3.3 (2011): 1265-1272.
  • Muralimanoharan, S., et al. "MIR-210 modulates mitochondrial respiration in placenta with preeclampsia." Placenta 33.10 (2012): 816-823.
  • Dai, Yongdong, et al. "MiR-210-3p protects endometriotic cells from oxidative stress-induced cell cycle arrest by targeting BARD1." Cell death & disease 10.2 (2019): 144.
  • Xu, Yawei, et al. "Seminal plasma miR‐210‐3p is a biomarker for screening dyszoospermia caused by varicocele." Andrologia (2019): e13244.
Related Products